Breast cancer progresses when over-expressed estrogen receptors (ER) increase transcriptional activity.[3] Treatment of advanced metastatic disease, therefore, will try to reduce circulating estrogens using aromatase inhibitors or block the receptors using selective ER modulators. Here, ESR1 is linked to metastatic neoplasm.